Active Ingredient(s): Tebentafusp-tebn
FDA Approved: * January 25, 2022
Pharm Company: * IMMUNOCORE LTD
Category: Cancer

Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer).[1][2][3] The most common side effects include cytokine release syndrome, rash, pyrexia (fever), pruritus (itching), fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting.[1][2] Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kimmtrak 100 ug/.5ml Intravenous Injection, Solution, Concentrate
NDC: 80446-401
Immunocore Commercial LLC